BlackRock Inc. Takes $196.97 Million Position in Collegium Pharmaceutical, Inc. $COLL

Key Points

• BlackRock acquired 5.44 million shares of Collegium Pharmaceutical during the second quarter, worth approximately $196.97 million and representing a 16.78% stake.
• Collegium reported quarterly EPS of $1.92, beating estimates of $1.72, while revenue rose 6.3% year over year to $199.88 million. The stock was trading at $26.44, near its 12-month low of $25.47.
• Analysts remain moderately bullish, with a consensus price target of $51.00, although several firms recently lowered their targets and some downgraded the stock to “hold.”

BlackRock Inc. bought a new position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 5,441,202 shares of the specialty pharmaceutical company's stock, valued at approximately $196,972,000. BlackRock Inc. owned about 16.78% of Collegium Pharmaceutical as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently bought and sold shares of COLL. Rubric Capital Management LP raised its stake in Collegium Pharmaceutical by 5.3% during the second quarter. Rubric Capital Management LP now owns 3,157,743 shares of the specialty pharmaceutical company's stock worth $93,374,000 after purchasing an additional 157,743 shares during the period. Vanguard Group Inc. grew its stake in shares of Collegium Pharmaceutical by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 2,256,254 shares of the specialty pharmaceutical company's stock valued at $104,465,000 after buying an additional 29,876 shares during the period. Janus Henderson Group PLC increased its holdings in shares of Collegium Pharmaceutical by 26.0% during the 1st quarter. Janus Henderson Group PLC now owns 1,825,651 shares of the specialty pharmaceutical company's stock worth $60,358,000 after buying an additional 377,073 shares during the last quarter. Renaissance Technologies LLC increased its holdings in shares of Collegium Pharmaceutical by 1.1% during the 4th quarter. Renaissance Technologies LLC now owns 1,617,349 shares of the specialty pharmaceutical company's stock worth $74,883,000 after buying an additional 18,160 shares during the last quarter. Finally, Principal Financial Group Inc. raised its position in shares of Collegium Pharmaceutical by 0.3% in the 4th quarter. Principal Financial Group Inc. now owns 1,313,662 shares of the specialty pharmaceutical company's stock worth $60,823,000 after buying an additional 3,891 shares during the period.

Collegium Pharmaceutical Trading Down 3.9%

NASDAQ:COLL opened at $26.44 on Friday. The business's 50-day moving average is $33.12 and its two-hundred day moving average is $35.13. The firm has a market capitalization of $860.89 million, a PE ratio of 21.32 and a beta of 0.73. Collegium Pharmaceutical, Inc. has a 12 month low of $25.47 and a 12 month high of $50.79. The company has a debt-to-equity ratio of 3.32, a current ratio of 1.03 and a quick ratio of 0.84.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last posted its earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.72 by $0.20. The business had revenue of $199.88 million during the quarter, compared to analyst estimates of $199.62 million. Collegium Pharmaceutical had a return on equity of 91.43% and a net margin of 5.93%.The company's revenue for the quarter was up 6.3% compared to the same quarter last year. During the same quarter last year, the firm earned $1.68 earnings per share. Research analysts predict that Collegium Pharmaceutical, Inc. will post 6.51 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently weighed in on COLL. Zacks Research cut Collegium Pharmaceutical from a "strong-buy" rating to a "hold" rating in a report on Tuesday, July 28th. Needham & Company LLC dropped their price target on Collegium Pharmaceutical from $56.00 to $46.00 and set a "buy" rating for the company in a research note on Thursday, August 6th. Barclays cut their price objective on Collegium Pharmaceutical from $56.00 to $48.00 and set an "overweight" rating on the stock in a report on Wednesday, August 19th. Weiss Ratings lowered Collegium Pharmaceutical from a "hold (c)" rating to a "hold (c-)" rating in a research note on Tuesday, August 11th. Finally, Wall Street Zen cut Collegium Pharmaceutical from a "buy" rating to a "hold" rating in a report on Saturday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $51.00.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company's core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company's principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source